A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 1
Abstract
Background: Colorectal cancer is one major health problem and cancer-related cause of death in cancer patients in countries such as Iran where the most cases are diagnosed in advanced stages. Objectives: To evaluate the incidence and severity of toxic effects in colorectal cancer patients who have been treated with two different schedules of combination of oxaliplatin and bolus/infusional 5-fluorouracil with leucovorin (FOLFOX) and to compare them. Methods: Medical records of 458 patients with colorectal cancer treated with FOLFOX 4 and modified FOLFOX 6 regimen between 2005 and 2014 were reviewed. Data from 96 eligible patients were analyzed. Fifty-six patients (58.3%) received FOLFOX 4 and 40 patients (41.7%) received modified FOLFOX 6. Results: The study included 96 patients, 39 of whom were males (40.6%) and 57 of whom were females (59.4%). The median age was 62 years (range: 38 - 87 years). The follow up duration was between 16 - 109 months with a median of 62 months. There was a statistically significant incidence rate of grade 1 toxicity of diarrhea as gastrointestinal (GI) toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.034), but there was not a statistically significant incidence rate of grade 1 toxicity of stomatitis as GI toxicity between the two regimens (P = 0.27).We observed a highly statistically significant incidence rate of grade 1 toxicity of neutropenia as hematologic toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P < 0.001), but we did not observe any statistically significant differences of grade 1 of thrombocytopenia as hematologic toxicity between the two regimens (P = 0.063). There was a statistically significant incidence rate of grade 1 neurotoxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.017). Conclusions: We showed that in colorectal cancer patients treated with modified FOLFOX6. Some of hematological and nonhematological complications were more than FOLFOX4 and they can be concerned.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP237281
- DOI -
- Views 59
- Downloads 0
The Molecular Mechanisms of Tobacco in Cancer Pathogenesis
Context: Studies have shown that cancer is a multi-factorial disease in its pathogenesis, in addition to genetic disorders, the effect of environmental factors can also be pointed. Among all environmental factors, tobacc...
Late Diagnosis, Smoking History and Socioeconomic Inequality in Gastric Carcinoma: A Decomposition Approach
Background An association between cancer survival and socioeconomic status (SES) has been evaluated for many different cancers but calculating socioeconomic inequality in survival...
Triple Therapy with Doxorubicin, Imatinib and Tamoxifen in Recurrence Desmoids Tumor Associated with Pregnancy: Case Report and Literature Review
Introduction: Desmoid tumors, also known as aggressive fibromatosis, grow slowly but are locally aggressive. The therapy strategy consists of surgery, and radiation. Systemic therapy with non-steroidal anti-inflammatory...
No Association Between Human Papillomavirus and Prostate Cancer
Background: The role of human papillomavirus (HPV) in prostate cancer is unclear. The aim of this study was to investigate the relationship between HPV and prostate cancer. Methods: In this case - control study, 133 par...
The Role of Echocardiography in Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients
Context: The incidence of breast malignancy is increasing and it became evident that chemotherapy protocols that are based on anthracyclinesandtrastuzumab, which are being used in these patients, have cardiotoxic effect....